Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945704 | 0.97 | MAPK1 (0.65) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL1787931 | 0.92 | MAPK1 (0.71) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL235921 | 0.89 | MAPK1 (0.81) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL1786754 | 0.87 | MAPK1 (0.79) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL9947121 | 0.87 | MAPK1 (0.79) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL15233919 | 0.86 | MAPK1 (0.58) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL20217140 | 0.84 | MAPK1 (0.59) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL16045158 | 0.84 | MAPK1 (0.59) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL812786 | 0.83 | MAPK1 (0.71) | MAPK1HIF1ATDP1CYP2D6SLC6A3 | |
| SCHEMBL505769 | 0.83 | MAPK1 (0.71) | MAPK1HIF1ATDP1CYP2D6SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | ACP1, ILK, BCAT2 | MAPK1 2083/4885HIF1A 2413/4885TDP1 1859/4885 |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | MAPK1 4777/4885HIF1A 2383/4885TDP1 57/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | MAPK1 4777/4885HIF1A 2383/4885TDP1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.